Protects against the main causes of cervical cancer, from which about 179,000 women died in 2020 in lower-income countries.
Protects against the main causes of cervical cancer, from which about 179,000 women died in 2020 in lower-income countries.
Latest articles about HPV Routine vaccines: HPV
HPV vaccine coverage increased from 7% in 2019 to 10% in 2022. This was largely driven by countries introducing the vaccine into their national immunisation programmes. By the end of 2022, 32 countries had successfully launched their HPV vaccine national programme with Gavi support, fully immunising more than 16.3 million girls since 2014, which translates to over 387,000 cervical cancer deaths averted with Gavi support.
In April 2022, the Strategic Advisory Group of Experts on Immunization (SAGE) recommended a one- or two-dose schedule for HPV vaccine; subsequently, the WHO position paper was released in December 2022. In response to this potential gamechanger for Gavi’s HPV vaccine programme – and to overcome the challenges and impact of the COVID-19 pandemic on HPV vaccine delivery – in December 2022, the Gavi Board approved the revitalisation of Gavi’s HPV vaccine programme. This revitalisation initiative committed to reach 86 million adolescent girls with HPV vaccine by 2025 through: (1) accelerating quality introductions; (2) rapidly improving global and national coverage; and (3) generating long- term programmatic sustainability.
With efforts underway to strengthen programme delivery and facilitate more introductions, and long-standing supply challenges easing thanks to increased vaccine production and the new one-dose recommendation, coverage is expected to further increase in the coming years.
Cervical cancer caused 179,000 deaths in 2020 in lower- income countries. However, human papillomavirus (HPV) is associated with over 90% of these cancers, and vaccination provides high protection against cervical cancer. The HPV vaccine has amongst the highest impact of all Gavi-supported vaccines, with 17.4 deaths averted per 1,000 children vaccinated, and is the key intervention towards achieving the global strategy for cervical cancer elimination.
HPV vaccination is critical to reducing cervical cancer, especially in lower-income countries with a high disease burden and less developed cervical cancer screening and treatment programmes. It is also a bridge to improving women’s and girls’ health through increased touchpoints with health services, and therefore an opportunity to positively impact gender equity.
Historically, the high cost of HPV vaccine, limited supply and challenges of reaching adolescent girls to deliver immunisation have been barriers to introduction in lower-income countries. Gavi is working to bridge the equity gap by providing support for HPV vaccine and ensuring sustainable prices. Gavi supports HPV vaccines for national introduction, with immunisation of multi-age cohorts of girls aged 9–14 years.
These objectives have been facilitated by an easing of global HPV vaccine supply constraints, the permissive recommendation by SAGE for a one-dose schedule (compared with the two-dose schedule) and the waning of COVID-19 pandemic-related delivery disruptions. Nonetheless, by end 2022, over 16 million girls had been reached with HPV vaccine with Gavi support.
In December 2022 the Gavi Board approved the revitalisation of the Alliance’s HPV vaccine programme with a US$ 600+ million investment through 2025. With the additional funding in place, the Alliance has set an ambitious goal to reach over 86 million girls with HPV vaccine by 2025, aiming to avert over 1.4 million future deaths from cervical cancer.
The revitalisation will allow Gavi to dedicate additional funding to help countries and partners reach more girls than ever with this life-saving vaccine – through expanded funding for vaccines, introduction and campaign costs;, and expanded support for technical assistance.
Gavi-eligible countries can also utilise health system strengthening (HSS) funding to develop tailored approaches to improve and sustain HPV vaccination coverage.
Gavi procures three HPV vaccines that have been prequalified by WHO. Through long-term agreements with manufacturers, supply is likely to be sufficient to meet the ongoing demand for delayed MAC catch-up campaigns and routine introductions, supported by the adoption of a one-dose schedule by countries, and suppliers ramping up production.
School-based targeting increases HPV vaccination rates
There are lessons to be learned from Punjab’s approach to increasing HPV vaccination rates.
WHO says just one dose of HPV vaccine protects against cervical cancer
Cervical cancer kills one woman every two minutes, but the need for two or three doses is a major reason why vaccine uptake has been slow – this finding should mean many more lives are saved through HPV vaccination.
Kenya’s HPV vaccine strategies re-activated for COVID-19
Strategies to ensure effective HPV vaccinations in Kenya have been modified to boost rollout of the COVID-19 vaccine.
With cervical cancer killing one woman every two minutes, rolling out the HPV vaccine that can almost entirely prevent this killer disease is essential.
Fighting cervical cancer in Lao PDR
In 2021, led by the Lao Women’s Union, Laos made a commitment to combat HPV.
Kenya on a drive to tackle cervical cancer
Kenya has been systematically rolling out the HPV vaccine – which prevents the leading cause of cervical cancer – in schools.
HPV vaccine cuts cervical cancer cases by nearly 90%
Real world data from the UK shows the value of vaccinating girls against human papilloma virus (HPV) when they are 12 to 13 years of age.
How to eliminate cervical cancer - an expert explains
COVID-19 has caused a decline in the delivery of human papillomavirus (HPV) vaccines that protect girls from cervical cancer. Anuradha Gupta, the Deputy CEO of Gavi, explains what we must do to create more access to these vaccines.
All roads lead to Ocean: how cancer treatment works in Tanzania
In Tanzania, the Ocean Road Cancer Institute is doing its part to ensure that people across the country can receive cancer treatment and care, regardless of their ability to pay.
Eliminating cervical cancer depends on global effort to ensure supply meets demand
Global access to HPV vaccine is vital, particularly in lower-income countries. Lessons learned from HPV roll-out could boost uptake of COVID-19 vaccines.
Can the world ever be cervical cancer-free?
As World Cancer Day approaches amidst the COVID-19 pandemic, it’s now more important than ever to ensure continued access to HPV vaccines to eliminate cervical cancer around the world.
How much of an impact do vaccines really have?
The world’s most comprehensive study reveals all! A new study looking at the impact of vaccinations in 98 countries over the past 20 years concludes that 37 million people are alive today thanks to vaccines.
Eligible countries can access detailed guidelines to manage the support they receive from Gavi.
